Ropes and Gray recommended Accutar Biotechnology in a strategic partnership with Evommune focused on the discovery of new small molecule drug candidates in chronic inflammatory diseases. The collaboration will leverage Accutar's artificial intelligence platform as well as Evommune's expertise in the design and development of oral small molecule therapies against targets that are the cause of chronic immune inflammatory diseases. He collaboration It was announced on November 28. Financial terms were not disclosed.
Accutar is a clinical-stage biotechnology company focused on AI-driven drug discovery. The company has a hybrid approach of computational drug design and wet lab validation.
Ropes & Gray team included life sciences transaction partner hannah england and intellectual property transaction associate Sameer Desai.
